Mazelsky joins the Acton, Massachusetts-based automated insulin delivery technology developer‘s board as an independent director.
“We are pleased to welcome Jay to Insulet’s board of directors,” said Insulet President and CEO Ashley McEvoy. “Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leadership position. We look forward to working with Jay and leveraging his insights to help advance our mission focused on transforming the lives of people with diabetes around the world.”
Mazelsky currently serves as executive chair of the board of directors at IDEXX Laboratories, an animal health diagnostics leader. He served as president and CEO there from October 2019 to May 2026 after holding previous positions there beginning in 2012.
Before IDEXX, Mazelsky served as SVP and GM, computed tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare. He also held various other strategic leadership roles over more than a decade at the Dutch medtech giant. Other previous roles included stints at Agilent Technologies and Hewlett Packard. He also serves on the Dentsply Sirona board.
“I’m honored to join Insulet’s board at such an exciting time in the Company’s growth journey,” said Mazelsky. “Insulet has built a strong category-leading business based on Omnipod’s unique AID system, clinical evidence and real-world outcomes, and I am truly inspired by the Company’s relentless commitment to reduce the burden of diabetes.”
